Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: idahoranch1 who wrote (53434)	12/13/2019 1:41:53 PM
From: allatwwk	2 Recommendations Recommended By ladyPI summer_sky Respond to of 63310

Happened to be overseas during the recent IMMU happenings. I'm a bit surprised the stock has done so well, I didn't expect the news (at least what I've seen) to move the needle. I did anticipate the secondary, though had a wide window on when (figured it had til mid 2020 to get done). Turns out, it was near the beginning of the window. I also anticipated the BLA resubmission. It was hard not to, given Behzad told the world when it was coming. At least this time, the resubmission happened roughly when promised. Given these things were essentially 'givens', I'm not certain why the shares jumped. Good for those who managed to net a very sweet return on the secondary (from $17.50 to $21 in a week or so), though I do dislike that much money left on the table. Good for all the IMMU longs and yeah, nice to see the shorts feeling some pain. With the share price bump, IMMU likely won't suffer much year-end tax-loss selling. Here's hoping the shares have seen the teens for the last time, ever. The upcoming year has a ton of potential -- though I can recall feeling similarly many times before.